Venture capital firms Canaan Partners and Bioqube Ventures led a $150m Series D round in CatalYm, a developer of innovative immunotherapies, with participation from Forbion, Omega Funds, Gilde Healthcare, Jeito Capital, Brandon Capital Partners and Novartis Venture Fund. "The recent data presented at ASCO highlight visugromab’s highly differentiated therapeutic profile and validate the ability of Phil and his team to expeditiously execute on the company’s clinical plan. As the company advances into expanded Phase 2b development, we are excited to provide our strategic guidance on the company’s trajectory toward changing the current treatment regimens for hard-to-treat solid tumor indications," Colleen Cuffaro, Canaan Partner.